<DOC>
	<DOCNO>NCT01992523</DOCNO>
	<brief_summary>The aim Mashed Or Just Integral pill TicagrelOr ( MOJITO ) study evaluate superiority Ticagrelor 180 mg LD mash pill versus Ticagrelor 180 mg LD integral pill orally administrate decrease residual platelet reactivity 1 hour administration among 70 patient STEMI ( ST segment elevation myocardial infarction ) undergo PPCI ( primary percutaneous coronary intervention ) bivalirudin monotherapy .</brief_summary>
	<brief_title>Mojito Study ( Mashed Or Just Integral Pill TicagrelOr ? )</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients present within 12 hour onset symptom STEMI Informed , write consent Age &lt; 18 year Age &gt; 75 year Active bleeding ; bleed diathesis ; coagulopathy Increased risk bradycardiac event History gastrointestinal genitourinary bleeding &lt; 2 month Major surgery last 6 week History intracranial bleed structural abnormality Suspected aortic dissection Any condition may put patient risk influence study result investigator 's opinion ( severe hemodynamic instability , know malignancy comorbid condition life expectancy &lt; 1 year ) Administration week index event clopidogrel , ticlopidine , prasugrel , ticagrelor , thrombolytic , bivalirudin , lowmolecular weight heparin fondaparinux . Concomitant oral IV therapy strong CYP3A inhibitor strong CYP3A inducer , CYP3A narrow therapeutic window Known relevant hematological deviation : Hb &lt; 10 g/dl , Thrombi . &lt; 100x10^9/l Use coumadin derivative within last 7 day Chronic therapy ticagrelor , prasugrel , clopidogrel ticlopidine Known severe liver disease , severe renal failure Known allergy study medication Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>antiplatelet</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
</DOC>